Galderma, one of the leaders in pure-play dermatology category present in approximately 90 countries, has announced that full results from the phase III OLYMPIA 1 trial, a 24 weeks study which evaluated the efficacy and safety of nemolizumab monotherapy in adults with moderate-to-severe prurigo nodularis, were published in JAMA Dermatology.
The clinical trial met both primary and all key secondary endpoints, showing that nemolizumab-treated patients had significantly higher improvements in itch and skin lesions when compared to those receiving placebo at week 16, with a rapid and clinically meaningful response on itch and sleep disturbance observed as early as week 4. Nemolizumab was well-tolerated, and its safety profile was generally consistent with previous studies.
These results, alongside the OLYMPIA 2 trial data, formed the basis of nemolizumab’s recent US FDA approval for the treatment of adults with prurigo nodularis. They demonstrate the potential of this treatment to rapidly and significantly provide relief from the most burdensome symptom for people with prurigo nodularis – itch.
The phase III OLYMPIA 1 trial enrolled 286 adult patients with moderate-to-severe prurigo nodularis. Results demonstrated that patients treated with nemolizumab monotherapy (without background topical corticosteroids or topical calcineurin inhibitors) showed clinically meaningful and statistically significant improvements in both primary endpoints, compared to placebo. After 16 weeks of treatment, more than three times as many nemolizumab-treated patients.
In the OLYMPIA 1 trial, a significantly higher proportion of nemolizumab-treated patients achieved an itch-free or nearly itch-free state as early as week 4 compared to those receiving placebo.
Nemolizumab is a first-in-class monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. IL-31 is a neuroimmune cytokine that is known to drive key signs and symptoms of prurigo nodularis.
Data were consistent with OLYMPIA 2 trial results, reinforcing the potential of nemolizumab monotherapy to demonstrate rapid and sustained improvements in core signs and symptoms of prurigo nodularis: skin lesions, itch and sleep disturbance – at week 16 and week 24.
Achieved an at least four-point improvement in itch intensity, as measured by the peak-pruritus numerical rating scale (PP-NRS), when compared to the placebo group (58.4% vs 16.7%; P<0.001).
Reached clearance or almost-clearance of skin lesions, when assessed using the investigator’s global assessment (score of 0 or 1 and a =2-point improvement from baseline), compared to the placebo group (26.3% vs 7.3%; P<0.01).
More than six times as many nemolizumab-treated patients achieved itch response when compared to the placebo group (41.1% vs 6.3%; P<0.001), as measured by a four-point or greater reduction in PP-NRS score.
More than twenty times as many nemolizumab-treated patients achieved a PP-NRS score of less than two, when compared to the placebo group (21.6% vs 1.0%; P<0.001). Results improved through to Week 16 (34.2% vs 4.2%; P<0.001).
Almost six times as many nemolizumab-treated patients demonstrated a four-point improvement in sleep disturbance, as measured by the sleep disturbance numerical rating scale, when compared to the placebo group (31.1% vs 5.2%; P<0.001). Results improved through to Week 16 (50.0% vs 11.5%; P<0.001).
These full results reinforce previous findings from the phase III OLYMPIA 2 trial, published in the New England Journal of Medicine, which demonstrated that nemolizumab rapidly and significantly improved itch and skin lesions in patients with prurigo nodularis, with clinically meaningful responses on itch observed as early as Week 4.2 The OLYMPIA trial programme is the largest phase III programme in prurigo nodularis completed to date, and the only one to include an open-label, long-term extension study.
The full phase III OLYMPIA 1 trial results add to the extensive body of evidence supporting nemolizumab’s potential to significantly and safely improve some of the most debilitating symptoms for people with prurigo nodularis – chronic itch, skin nodules, and poor sleep quality – which can be all consuming and have a knock-on effect on patients’ overall quality of life and mental health.
Based on data from the OLYMPIA clinical trial program, nemolizumab has been approved by the US FDA for the treatment of adults with prurigo nodularis under the name Nemluvio. Galderma also has marketing authorization applications for nemolizumab in both prurigo nodularis and atopic dermatitis under review by multiple additional regulatory authorities, including the EMA and via the Access Consortium framework in countries such as Australia, Singapore, and Switzerland, as well as Canada, Brazil, and South Korea. Submissions to regulatory authorities in additional countries are ongoing.
The US FDA has also accepted for review Galderma’s BLA for nemolizumab for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis, with a decision expected by the end of the year.
Galderma also has marketing authorization applications for nemolizumab in both prurigo nodularis and atopic dermatitis under review by multiple additional regulatory authorities, including the European Medicines Agency and via the Access Consortium framework in countries such as Australia, Singapore, and Switzerland, as well as in Canada, Brazil, and South Korea.
|